RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA (AML)
Clinical trials for RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA (AML) explained in plain language.
Never miss a new study
Get alerted when new RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA (AML) trials appear
Sign up with your email to follow new studies for RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA (AML), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Off-the-Shelf immune cells take aim at Hard-to-Treat leukemia
Disease control Not yet recruitingThis early-phase trial is testing an experimental therapy called GT737 for adults with acute myeloid leukemia (AML) that has come back or not responded to standard treatment. GT737 uses specially engineered immune cells (iNKT cells) that are made in large batches and can be given…
Matched conditions: RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA (AML)
Phase: EARLY_PHASE1 • Sponsor: Grit Biotechnology • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New hope for tough leukemia: experimental therapy CT1390B enters first human tests
Disease control Not yet recruitingThis early-stage study tests a new drug, CT1390B, in 18 adults whose acute myeloid leukemia has come back or not responded to standard treatments. The main goals are to check safety, find the right dose, and see if the drug can shrink or clear the cancer. Participants must be bet…
Matched conditions: RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA (AML)
Phase: PHASE1 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
Experimental CAR-T therapy takes on tough leukemia
Disease control Not yet recruitingThis early-stage trial tests a new treatment called CT0991, which uses a patient's own immune cells engineered to attack leukemia cells. It will enroll 24 adults with acute myeloid leukemia that has returned or not responded to standard therapy. The main goals are to check safety…
Matched conditions: RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA (AML)
Phase: PHASE1 • Sponsor: MEI HENG • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC